These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26025876

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
    Ohashi M, Oyama T, Miyachi H.
    Bioorg Med Chem Lett; 2015 Jul 01; 25(13):2639-44. PubMed ID: 25987371
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
    Miyachi H.
    Int J Mol Sci; 2023 Feb 15; 24(4):. PubMed ID: 36835351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y, Coales SJ, Morrow JA, Molnar KS, Tuske SJ, Southern MR, Griffin PR.
    Protein Sci; 2006 Aug 15; 15(8):1883-92. PubMed ID: 16823031
    [Abstract] [Full Text] [Related]

  • 7. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY, Koh M, Bae H, An DR, Im HN, Kim HS, Yoon JY, Yoon HJ, Han BW, Park SB, Suh SW.
    Biochim Biophys Acta Proteins Proteom; 2017 Jun 15; 1865(6):674-681. PubMed ID: 28342850
    [Abstract] [Full Text] [Related]

  • 8. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R, Saccoccia F, Scotti E, Crestani M, Godio C, Gilardi F, Loiodice F, Fracchiolla G, Laghezza A, Tortorella P, Lavecchia A, Novellino E, Mazza F, Aschi M, Pochetti G.
    J Med Chem; 2008 Dec 25; 51(24):7768-76. PubMed ID: 19053776
    [Abstract] [Full Text] [Related]

  • 9. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K.
    J Mol Biol; 2009 Jan 09; 385(1):188-99. PubMed ID: 18977231
    [Abstract] [Full Text] [Related]

  • 10. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists.
    Liberato MV, Nascimento AS, Ayers SD, Lin JZ, Cvoro A, Silveira RL, Martínez L, Souza PC, Saidemberg D, Deng T, Amato AA, Togashi M, Hsueh WA, Phillips K, Palma MS, Neves FA, Skaf MS, Webb P, Polikarpov I.
    PLoS One; 2012 Jan 09; 7(5):e36297. PubMed ID: 22649490
    [Abstract] [Full Text] [Related]

  • 11. Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor gamma allows ligand identification and characterization.
    Zorrilla S, Garzón B, Pérez-Sala D.
    Anal Biochem; 2010 Apr 01; 399(1):84-92. PubMed ID: 20025845
    [Abstract] [Full Text] [Related]

  • 12. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
    Miyamae Y.
    Biol Pharm Bull; 2021 Apr 01; 44(9):1185-1195. PubMed ID: 34471046
    [Abstract] [Full Text] [Related]

  • 13. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC, Bernardes A, Silveira RL, Yuan J, Campos JL, Saidemberg DM, Palma MS, Cvoro A, Ayers SD, Webb P, Reinach PS, Skaf MS, Polikarpov I.
    Mol Pharmacol; 2012 Jun 01; 81(6):788-99. PubMed ID: 22391103
    [Abstract] [Full Text] [Related]

  • 14. Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands.
    Waku T, Shiraki T, Oyama T, Morikawa K.
    FEBS Lett; 2009 Jan 22; 583(2):320-4. PubMed ID: 19101554
    [Abstract] [Full Text] [Related]

  • 15. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH, Coumar MS, Leou JS, Wu JS, Shiao HY, Lin CH, Lin WH, Lien TW, Chen X, Hsu JT, Chao YS, Huang CF, Lyu PC, Hsieh HP, Wu SY.
    ChemMedChem; 2010 Oct 04; 5(10):1707-16. PubMed ID: 20734309
    [Abstract] [Full Text] [Related]

  • 16. Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists.
    Tanaka Y, Gamo K, Oyama T, Ohashi M, Waki M, Matsuno K, Matsuura N, Tokiwa H, Miyachi H.
    Bioorg Med Chem Lett; 2014 Aug 15; 24(16):4001-5. PubMed ID: 25017035
    [Abstract] [Full Text] [Related]

  • 17. Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.
    Muralikumar S, Vetrivel U, Narayanasamy A, N Das U.
    Lipids Health Dis; 2017 Jan 21; 16(1):17. PubMed ID: 28109294
    [Abstract] [Full Text] [Related]

  • 18. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A, Kamata S, Satta C, Machida Y, Uchii K, Terasawa K, Nemoto A, Oyama T, Ishii I.
    Biol Pharm Bull; 2021 Jan 21; 44(9):1210-1219. PubMed ID: 34471049
    [Abstract] [Full Text] [Related]

  • 19. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.
    ChemMedChem; 2011 Apr 04; 6(4):633-53. PubMed ID: 21400663
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.